A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Trial Profile

A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Added to Chlorambucil Versus Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Ofatumumab (Primary) ; Chlorambucil
  • Indications Chronic lymphocytic leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPLEMENT 1
  • Sponsors Genmab; GlaxoSmithKline; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Jun 2017 Planned End Date changed from 16 Jun 2022 to 1 Jul 2022.
    • 21 May 2015 As per a Genmab media release, results from this trial will be presented at the 20th Congress of the European Hematology Association (EHA) in Vienna, June 11-14.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top